

PB 100 of 2020

National Health (Pharmaceutical Benefits) Legislation Amendment (Continuing Treatment during Coronavirus Pandemic) Instrument 2020 (No. 2)

I, Thea Connolly, as delegate of the Minister for Health, make the following instrument.

Dated 29 September 2020

Thea Connolly Assistant Secretary Pricing and PBS Policy Branch Technology Assessment and Access Division Department of Health

Contents

1 Name1	
2 Commencement	1
3 Authority	1
4 Schedules	1
chedule 1—Amendments	2
Part 1—Amendments of main listing instrument	2
National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of	
2012)	2
Part 2—Amendments of special arrangement	6
National Health (Highly specialised drugs program) Special Arrangement 2010 (PB 116 of 2010)	6

1 Name

- (1) This instrument is the National Health (Pharmaceutical Benefits) Legislation Amendment (Continuing Treatment during Coronavirus Pandemic) Instrument 2020 (No. 2).
- (2) This instrument may also be cited as PB 100 of 2020.

2 Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. The whole of this instrument	The day after this instrument is registered.	
Note:	This table relates only to the provisions of this instrumen not be amended to deal with any later amendments of thi	

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under the following:

- (a) subsection 85(7) of the *National Health Act 1953*;
- (b) subsection 100(2) of the National Health Act 1953.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

Part 1—Amendments of main listing instrument

National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012)

1 Subsection 10A(3)

Omit "1 October 2020", substitute "1 April 2021".

2 Schedule 6

Omit table and substitute:

Pharmaceutical items with modified prescription circumstances during COVID-19 pandemic			
Listed drug	Form	Manner of administration	
Abatacept	Injection 125 mg in 1 mL single dose autoinjector	Injection	
Abatacept	Injection 125 mg in 1 mL single dose pre-filled syringe	Injection	
Abatacept	Powder for I.V. infusion 250 mg	Injection	
Adalimumab	Injection 20 mg in 0.4 mL pre-filled syringe	Injection	
Adalimumab	Injection 40 mg in 0.8 mL pre-filled syringe	Injection	
Adalimumab	Injection 40 mg in 0.8 mL pre-filled syringe, 6	Injection	
Adalimumab	Injection 40 mg in 0.8 mL pre-filled pen	Injection	
Adalimumab	Injection 40 mg in 0.8 mL pre-filled pen, 4	Injection	
Adalimumab	Injection 40 mg in 0.8 mL pre-filled pen, 6	Injection	
Ambrisentan	Tablet 5 mg	Oral	
Ambrisentan	Tablet 10 mg	Oral	
Baricitinib	Tablet 2 mg	Oral	
Baricitinib	Tablet 4 mg	Oral	
Benralizumab	Injection 30 mg in 1 mL single dose pre-filled syringe	Injection	
Benralizumab	Injection 30 mg in 1 mL single dose pre-filled pen	Injection	
Bosentan	Tablet 62.5 mg (as monohydrate)	Oral	
Bosentan	Tablet 125 mg (as monohydrate)	Oral	
Certolizumab pegol	Injection 200 mg in 1 mL single use pre-filled syringe	Injection	
Certolizumab pegol	Solution for injection 200 mg in 1 mL pre-filled pen	Injection	
Dornase alfa	Solution for inhalation 2.5 mg (2,500 units) in 2.5 mL	Inhalation	
Epoprostenol	Powder for I.V. infusion 500 micrograms (as sodium)	Injection	
Epoprostenol	Powder for I.V. infusion 500 micrograms (as sodium) with 2 vials diluent 50 mL	Injection	

2

Epoprostenol	Powder for I.V. infusion 1.5 mg (as sodium)	Injection
Epoprostenol	Powder for I.V. infusion 1.5 mg (as sodium) with 2 vials diluent 50 mL	Injection
Etanercept	Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL	Injection
Etanercept	Injection 50 mg in 1 mL single use auto-injector, 4	Injection
Etanercept	Injections 50 mg in 1 mL single use pre-filled syringes, 4	Injection
Golimumab	Injection 50 mg in 0.5 mL single use pre-filled pen	Injection
Golimumab	Injection 50 mg in 0.5 mL single use pre-filled syringe	Injection
Golimumab	Injection 100 mg in 1 mL single use pre-filled pen	Injection
Guselkumab	Injection 100 mg in 1 mL single use pre-filled syringe	Injection
lloprost	Solution for inhalation 20 micrograms (as trometamol) in 2 mL	Inhalation
Infliximab	Powder for I.V. infusion 100 mg	Injection
Ivacaftor	Sachet containing granules 50 mg	Oral
Ivacaftor	Sachet containing granules 75 mg	Oral
Ivacaftor	Tablet 150 mg	Oral
Ixekizumab	Injection 80 mg in 1 mL single dose pre-filled pen	Injection
Lenalidomide	Capsule 5 mg	Oral
Lenalidomide	Capsule 10 mg	Oral
Lenalidomide	Capsule 15 mg	Oral
Lenalidomide	Capsule 25 mg	Oral
Lumacaftor with ivacaftor	Sachet containing granules, lumacaftor 100 mg and ivacaftor 125 mg	Oral
Lumacaftor with ivacaftor	Sachet containing granules, lumacaftor 150 mg and ivacaftor 188 mg	Oral
Lumacaftor with ivacaftor	Tablet containing lumacaftor 100 mg with ivacaftor 125 mg	Oral
Lumacaftor with ivacaftor	Tablet containing lumacaftor 200 mg with ivacaftor 125 mg	Oral
Macitentan	Tablet 10 mg	Oral
Mannitol	Pack containing 280 capsules containing powder for inhalation 40 mg and 2 inhalers	Inhalation by mouth
Mepolizumab	Powder for injection 100 mg	Injection
Mepolizumab	Injection 100 mg in 1 mL single dose pre-filled pen	Injection
Montelukast	Tablet, chewable, 4 mg (as sodium)	Oral
Montelukast	Tablet, chewable, 5 mg (as sodium)	Oral
Nintedanib	Capsule 100 mg	Oral
Nintedanib	Capsule 150 mg	Oral
Omalizumab	Injection 75 mg in 0.5 mL single dose pre-filled syringe	Injection
Omalizumab	Injection 150 mg in 1 mL single dose pre-filled syringe	Injection

Schedule 1 Amendments Part 1 Amendments of main listing instrument

Pirfenidone	Capsule 267 mg	Oral
Pirfenidone	Tablet 267 mg	Oral
Pirfenidone	Tablet 801mg	Oral
Pomalidomide	Capsule 3 mg	Oral
Pomalidomide	Capsule 4 mg	Oral
Riociguat	Tablet 500 micrograms	Oral
Riociguat	Tablet 1 mg	Oral
Riociguat	Tablet 1.5 mg	Oral
Riociguat	Tablet 2 mg	Oral
Riociguat	Tablet 2.5 mg	Oral
Risankizumab	Injection 75 mg in 0.83 mL pre-filled syringe	Injection
Rituximab	Solution for I.V. infusion 500 mg in 50 mL	Injection
Secukinumab	Injection 150 mg in 1 mL pre-filled pen	Injection
Sildenafil	Tablet 20 mg (as citrate)	Oral
Somatropin	Injection 0.4 mg (1.2 i.u.) with diluent in single use syringe (without preservative)	Injection
Somatropin	Injection 0.6 mg (1.8 i.u.) with diluent in single use syringe (without preservative)	Injection
Somatropin	Injection 0.8 mg (2.4 i.u.) with diluent in single use syringe (without preservative)	Injection
Somatropin	Injection 1 mg (3 i.u.) with diluent in single use syringe (without preservative)	Injection
Somatropin	Injection 1.2 mg (3.6 i.u.) with diluent in single use syringe (without preservative)	Injection
Somatropin	Injection 1.4 mg (4.2 i.u.) with diluent in single use syringe (without preservative)	Injection
Somatropin	Injection 1.6 mg (4.8 i.u.) with diluent in single use syringe (without preservative)	Injection
Somatropin	Injection 1.8 mg (5.4 i.u.) with diluent in single use syringe (without preservative)	Injection
Somatropin	Injection 2 mg (6 i.u.) with diluent in single use syringe (without preservative)	Injection
Somatropin	Injection 4 mg (12 i.u.) vial with diluent (with preservative)	Injection
Somatropin	Injection 18 i.u. (6 mg) cartridge with 3.15 mL diluent (with preservative)	Injection
Somatropin	Injection 72 i.u. (24 mg) cartridge with 3.15 mL diluent (with preservative)	Injection
Somatropin	Powder for injection 5 mg (15 i.u.) with diluent in pre-filled pen (with preservative)	Injection
Somatropin	Powder for injection 12 mg (36 i.u.) with diluent in pre-filled pen (with preservative)	Injection
Somatropin	Injection 36 i.u. (12 mg) cartridge with 3.15 mL diluent (with preservative)	Injection
Somatropin	Solution for injection 5 mg (15 i.u.) in 1.5 mL cartridge	Injection

4

	olution for injection 5 mg (15 i.u.) in 1.5 mL cartridge vith preservative)	Injection
	olution for injection 6 mg (18 i.u.) in 1.03 mL cartridge vith preservative)	Injection
	olution for injection 10 mg (30 i.u.) in 1.5 mL cartridge vith preservative)	Injection
	olution for injection 10 mg (30 i.u.) in 1.5 mL cartridge vith preservative) in pre-filled pen	Injection
•	olution for injection 10 mg (30 i.u.) in 2 mL cartridge vith preservative)	Injection
	olution for injection 12 mg (36 i.u.) in 1.5 mL cartridge vith preservative)	Injection
	olution for injection 15 mg (45 i.u.) in 1.5 mL cartridge vith preservative)	Injection
	olution for injection 15 mg (45 i.u.) in 1.5 mL cartridge vith preservative) in pre-filled pen	Injection
	olution for injection 20 mg (60 i.u.) in 2.5 mL cartridge with preservative)	Injection
Tadalafil Ta	ablet 20 mg	Oral
	ack containing 28 tablets tezacaftor 100 mg with acaftor 150 mg and 28 tablets ivacaftor 150 mg	Oral
Tildrakizumab In	jection 100 mg in 1 mL single dose pre-filled syringe	Injection
Tocilizumab Co	concentrate for injection 80 mg in 4 mL	Injection
Tocilizumab Co	oncentrate for injection 200 mg in 10 mL	Injection
Tocilizumab Co	oncentrate for injection 400 mg in 20 mL	Injection
Tocilizumab In	jection 162 mg in 0.9 mL single use pre-filled pen	Injection
Tocilizumab In	ijection 162 mg in 0.9 mL single use pre-filled syringe	Injection
Tofacitinib Ta	ablet 5 mg	Oral
Upadacitinib Ta	ablet 15 mg	Oral
Ustekinumab In	jection 45 mg in 0.5 mL	Injection
Ustekinumab So	olution for I.V. infusion 130 mg in 26 mL	Injection
Vedolizumab Pe	owder for injection 300 mg	Injection

Part 2—Amendments of special arrangement

National Health (Highly specialised drugs program) Special Arrangement 2010 (PB 116 of 2010)

3 Subsection 9AA(3)

Omit "1 October 2020", substitute "1 April 2021".

6